TFC ‐1326 Compound Reduces Clinical Signs of Skin Aging. Evidence From In Vitro Human Adipose and Skin Models and Pilot Clinical Trial
Journal of Cosmetic Dermatology · 2025
DOI: 10.1111/jocd.16679 ↗Kurz gefasst
Klinische Studie in der Zeitschrift Journal of Cosmetic Dermatology, 2025. Verfasst von Géraldine Deliencourt-Godefroy und 7 weiteren Autor:innen. Beteiligte Einrichtung: TFChem (Sirona Biochem Corp), Val-de-Reuil, France. Hauptthemen laut MEDLINE: Skin Aging. Die Arbeit nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: TFChem (Sirona Biochem Corp).
Abstract (Originalsprache)
Background
Anti‐freeze Glycoproteins (AFGPs) were described to preserve biological materials and protect them from different stresses.
Aims
The effects of a synthetic anti‐freeze glycoprotein‐based compound, TFC‐1326, on human skin quality and its biological actions were studied.
Methods
The effects of various concentrations of TFC‐1326 on the biology of human preadipocytes, differentiated in the proinflammatory microenvironment, and on human fibroblasts grown in coculture with human mature adipocytes or monocultured in stress conditions were investigated in, in vitro studies. Additionally, the efficacy of a 1% TFC‐1326 topical cream was evaluated in a clinical investigation on the skin biology and appearance of 20 women aged between 40 and 65 years throughout 84 days of application.
Results
The in vitro studies revealed that TFC‐1326 mitigated the deleterious effects of a proinflammatory cytokine cocktail produced by human macrophages, by restoring preadipocyte adipogenic capacity and by reducing their fibroinflammatory state. TFC‐1326 also stimulated the proliferative capacity of dermal fibroblasts co‐cultured with mature adipocytes as well as their production of hyaluronic acid and procollagen type I, while decreasing IL6 secretion and increasing fibroblast viability. Furthermore, daily 1% TFC‐1326 topical cream application, measurably improved skin radiance and laxity, as well as skin density. Finally, significant reductions of the volume and depth of the crow's feet wrinkles were also observed.
Conclusions
The compound TFC‐1326 significantly improved the physiological appearance and cellular functions of aging skin.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- TFChem (Sirona Biochem Corp), Val-de-Reuil, France.
- DIVA Expertise, Toulouse, France.
- Gredeco, Paris, France.
ORCID-Profile: Sylvie Boisnic, Mayoura Keophiphath
Förderung
- TFChem (Sirona Biochem Corp)
Zitieren
APA
Deliencourt-Godefroy, G., Legoedec, J., Bourdens, M., Juin, N., Nguyen, L. T., Branchet, M. C., Boisnic, S., & Keophiphath, M. (2025). TFC ‐1326 Compound Reduces Clinical Signs of Skin Aging. Evidence From In Vitro Human Adipose and Skin Models and Pilot Clinical Trial. Journal of Cosmetic Dermatology. https://doi.org/10.1111/jocd.16679
Vancouver
Deliencourt-Godefroy G, Legoedec J, Bourdens M, Juin N, Nguyen LT, Branchet MC, et al. TFC ‐1326 Compound Reduces Clinical Signs of Skin Aging. Evidence From In Vitro Human Adipose and Skin Models and Pilot Clinical Trial. Journal of Cosmetic Dermatology. 2025. doi:10.1111/jocd.16679
BibTeX
@article{DeliencourtGodefroy2025,
author = {Deliencourt-Godefroy, Géraldine and Legoedec, Jocelyne and Bourdens, Marion and Juin, Noémie and Nguyen, Linh-Trang and Branchet, Marie-Christine and Boisnic, Sylvie and Keophiphath, Mayoura},
title = {TFC ‐1326 Compound Reduces Clinical Signs of Skin Aging. Evidence From In Vitro Human Adipose and Skin Models and Pilot Clinical Trial},
journal = {Journal of Cosmetic Dermatology},
year = {2025},
doi = {10.1111/jocd.16679}
}
EUVIMED